Design Therapeutics (DSGN) Interest Coverage Ratio (2020 - 2026)
Design Therapeutics (DSGN) reported Interest Coverage Ratio of 5.87 for Q1 2026, up 26.93% on a YoY basis from 4.63 in Q1 2025, and up 29.35% sequentially from 8.31 in Q4 2025.
Design Therapeutics (DSGN) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Interest Coverage Ratio data on file, last reported at 5.87 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 26.93% year-over-year to 5.87; the trailing twelve-month figure through Mar 2026 stood at 23.47 (down 231.28% YoY), and the FY2025 full-year result was 0.0, up 53.41% from the prior year.
- Interest Coverage Ratio improved to 5.87 in Q1 2026, from 8.31 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.0 in Q4 2022 to a low of 14.66 in Q3 2023.
- A 5-year average of 6.76 and a median of 6.82 in 2024 frame the typical range for Interest Coverage Ratio.
- Peak annual rise in Interest Coverage Ratio reached 51.22% in 2024, while the deepest fall reached 46604.93% in 2024.
- Tracing DSGN's Interest Coverage Ratio over 5 years: stood at 0.0 in 2022, then sank by 636.27% to 0.01 in 2023, then sank by 46604.93% to 6.33 in 2024, then slumped by 31.29% to 8.31 in 2025, then climbed by 29.35% to 5.87 in 2026.
- Business Quant data shows DSGN's Interest Coverage Ratio at 5.87 in Q1 2026, 8.31 in Q4 2025, and 8.51 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | -5.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.87 |
| Dec 31, 2025 | -8.31 |
| Sep 30, 2025 | -8.51 |
| Jun 30, 2025 | -7.87 |
| Mar 31, 2025 | -8.04 |
| Dec 31, 2024 | -6.33 |
| Sep 30, 2024 | -7.15 |
| Jun 30, 2024 | -6.82 |
| Mar 31, 2024 | -6.56 |
| Dec 31, 2023 | -0.01 |
| Sep 30, 2023 | -14.66 |
| Jun 30, 2023 | -11.27 |
| Mar 31, 2023 | -5.19 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | -4.97 |
| Jun 30, 2022 | -3.24 |
| Mar 31, 2022 | -10.11 |
| Sep 30, 2021 | -2.45 |
| Jun 30, 2021 | -1.64 |
| Mar 31, 2021 | -7.30 |